Melissa F Guerra, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 5980 9th St, Ft Belvoir, VA 22060 Phone: 571-231-1210 Fax: 571-231-6808 |
News Archive
World powers have reached an accord, after weeks of tough talks, on a document to be adopted at a Millennium Development summit this month for which [U.N.] Secretary General Ban Ki-moon is seeking billions of dollars of new funding,Agence France-Presse reports in an article that describes how representatives from donor and developing nations debated how best to pay for a kick start to the ambitious development goals first set at the Millennium summit in 2000.
Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.
Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.
Researchers at the Yerkes National Primate Research Center are the first to demonstrate that a combination of drug therapies targeting the region of the brain that controls drug abuse and addiction significantly reduces cocaine use in nonhuman primates.
A somatic mutation in the ATRX gene has recently been shown as a potential molecular marker for aggressive brain tumors, such as gliomas, neuroblastomas and pancreatic neuroendocrine tumors. Now, for the first time, researchers at Penn's Abramson Cancer Center have found that the same mutated gene may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas (PCC/PGL) that become malignant.
› Verified 6 days ago